研究者情報
検索ページ

（最終更新日：2024-04-10 11:26:32）   アライ　ヒロユキ   ARAI HIROYUKI   新井裕之    所属   医学部医学科 臨床腫瘍学    職種   講師

■ 学術雑誌 1. 原著　 Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID) 2024/04 2. 総説・解説　 Microsatellite instability: A 2024 update 2024/03 3. 原著　 Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer 2024/02 4. 原著　 CCR5 and CCL5 gene expression in colorectal cancer: comprehensive profiling and clinical value 2024/01 5. 原著　 Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials 2023/12 6. 原著　 Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer. 2023/05 7. 原著　 Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials. 2023/02 8. 原著　 Mutational analysis of microsatellite-stable gastrointestinal cancer with high tumour mutational burden: a retrospective cohort study 2023/02 9. 原著　 Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials 2022/09 10. 原著　 Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial 2022/09 11. 原著　 fdrci: FDR confidence interval selection and adjustment for large-scale hypothesis testing. 2022/06 12. 原著　 The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. 2022/05 13. 原著　 Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers 2022/03 14. 原著　 Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment 2022/03 15. 原著　 Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer 2021/11 16. 原著　 Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G 2021/10 17. 原著　 Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer 2021/10 18. 原著　 Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing 2021/09 19. 原著　 Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications 2021/09 20. 原著　 Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy 2021/07 21. 原著　 Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer 2021/07 22. 原著　 Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer 2021/06 23. 原著　 The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer 2021/03 24. 原著　 Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study 2021/02 25. 総説・解説　 がん化学療法の薬はや調べノート2020・2021年版 2021/02 26. 総説・解説　 がん化学療法の薬はや調べノート2020・2021年版 2021/02 27. 原著　 RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC 2021/01 28. 原著　 Molecular characterization of appendiceal goblet cell carcinoid 2020/12 29. 原著　 Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 2020/11 30. 症例報告　 Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report 2020/11 31. 原著　 The impact of ARID1A mutation on molecular characteristics in colorectal cancer 2020/11 32. 原著　 Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer 2020/04 33. 総説・解説　 Recent Developments of Systemic Chemotherapy for Gastric Cancer 2020/04 34. 原著　 AMPK Variant, a Candidate of Novel Predictor for Chemotherapy in Metastatic Colorectal Cancer: A Meta-Analysis Using TRIBE, MAVERICC and FIRE3 2019/10 35. 総説・解説　 Molecular insight of regorafenib treatment for colorectal cancer 2019/10 36. 原著　 Analysis of fistula formation of T4 esophageal cancer patients treated by chemoradiotherapy. 2019/09 37. 原著　 Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. 2019/07 38. 原著　 Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer 2019/06 39. 原著　 Molecular Profiling of Appendiceal Adenocarcinoma and Comparison With Right-sided and Left-sided Colorectal Cancer 2019/05 40. 総説・解説　 後方ライン治療におけるICのポイント 2019/04 41. 総説・解説　 肝機能障害への対応 2019/04 42. 原著　 Co-operative groups in the development of chemotherapy for gastric cancer. (Review Article (Invited)) 2019/03 43. 原著　 Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study. 2019/03 44. 総説・解説　 後方ライン治療におけるICのポイント 2018/11 45. 総説・解説　 胃癌・RAM(単剤, RAM+PTX) 2018/06 46. 総説・解説　 がん化学療法の薬はや調べノート2019・2020年版 2018/05 47. 総説・解説　 肝機能障害への対応 2018 48. 原著　 Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib 2017/12 49. 原著　 がん患者の終末期医療における看取り場所の聴取後の在宅がん緩和医療移行の実態 2017/12 50. 原著　 "Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib" 2017/11 51. 総説・解説　 Profile of trifluridine/tipiracil hydrochloride in the treatment of metastatic colorectal cancer: efficacy, safety, and place in therapy 2017/09 52. 総説・解説　 ①進行大腸がんの一次治療でFOLFOXIRI療法を用いる場合の注意点、②大腸癌の分子標的治療薬の作用機序の違いを考慮した治療戦略の進め方、③分子標的治療に伴う有害事象とその対応 (骨髄抑制、発熱性好中球減少症) 2017/09 53. 総説・解説　 切除不能・再発進行胃がんの治療戦略 state-of-art 2017/07 54. 総説・解説　 胃癌RAM (単剤、PTX+RAM) 2017/06 55. 総説・解説　 StageⅣ大腸癌に対する治療戦略：日本と欧米の比較 2017/05 56. 総説・解説　 胃癌化学療法の選択のポイント：術後補助化学療法 2017/02 5件表示 全件表示(56件)

■ 著書 1. 部分執筆　 消化管がん（食道、胃、大腸）診療におけるゲノム医療の位置づけ「腫瘍内科」 2023/06

■ 学会発表 1. Clinical significance of plasma-based comprehensive genomic profiling in metastatic colorectal cancer by RAS/BRAF status （口頭発表，一般） 2024/02/24 2. ゲノムガイドシステムを用いた包括的がんゲノムプロファイリングの実装データの構築 （口頭発表） 2024/02/24 3. 患者と主治医の抗がん剤による副作用のつらさと休薬希望度の差に関する意識調査 （口頭発表） 2024/02/24 4. A feasibility study to evaluate clinical utility of stress data collection in cancer patients treated with chemotherapy （口頭発表） 2024/02/22 5. Clinical course of skin rashes caused by neoadju-vant gemcitabine plus S-1 for resectable pancre-atic cancer （口頭発表） 2024/02/22 6. Establishing real-world data on actual advanced gastric cancer therapy using CyberOncology®: A feasibility study （口頭発表） 2024/02/22 7. A phase II trial of CapeOX plus nivolumab for early relapsed HER2-negative gastric cancer (JACCRO GC-11: FirSTAR trial). （ポスター） 2024/01/18 8. 免疫チェックポイント阻害薬による間質性肺炎に対する治療実態調査 （口頭発表） 2023/10/21 9. がん種別の包括的ゲノムプロファイリング（CGP）検査に基づいた治療提案と治療到達性 （口頭発表，一般） 2023/10/19 10. がん遺伝子パネル検査の解析成功率の向上を目的とした後方視的解析 （ポスター） 2023/07 11. Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB). （ポスター） 2023/06 12. A study to evaluate the clinical utility of stress data collection in cancer patients treated with chemotherapy （ポスター） 2023/03/17 13. がん薬物療法患者におけるストレスデータ収集の有用性に関する研究 （ポスター） 2023/03/17 14. 切除不能進行大腸癌におけるCDC37遺伝子発現のレゴラフェニブ療法の効果予測 （口頭発表） 2023/03/16 15. 胃癌患者における免疫関連有害事象の予測因子としての自己免疫疾患関連抗体の臨床的意義 （口頭発表） 2023/02/25 16. Treatment for elderly gastric cancer patients-Geriatric assessment and clinical outcomes- （口頭発表） 2023/02/24 17. 胃癌ゲノムプロファイリングによるdruggable alterationの同定 （口頭発表） 2023/02 18. 高齢胃癌患者における高齢者機能評価と臨床経過 （口頭発表） 2023/02 19. リアルワールドデータ（RWD）から見た小腸癌のゲノムランドスケープ （口頭発表） 2022/10 20. 食道扁平上皮癌・胃食道接合部癌におけるctDNAを用いた治療戦略 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2022/09/25 21. 切除可能大腸がん高齢患者の高齢者機能評価と臨床経過 （ポスター） 2022/06/18 22. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC). （ポスター） 2022/06/04 23. Somatostatin receptor: a potential new therapeutic target for primary mucinous neoplasm of the appendix. （口頭発表） 2022/02 24. 進行固形がん患者における免疫チェックポイント阻害薬導入前の抗体検査と免疫関連有害事象との関連性  2021/02/19 25. Multi-gene panel testing in patients with gastro-intestinal cancers: A retrospective study. （口頭発表，一般） 2020/10/23 26. 高齢者胃癌に対する治療の工夫 （口頭発表，シンポジウム・ワークショップ・パネルディスカッション等） 2020/10/22 27. 血管新生阻害薬による化学療法中に下腸間膜動静脈瘻を合併した大腸癌症例 （ポスター，一般） 2020/08/11 28. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors (ICIs) in advanced cancer patients （口頭発表） 2019/10/24 29. Association of gastric acid suppression with efficacy of immune checkpoint inhibitors （口頭発表） 2019/07/20 30. 胃がん栄養 （ポスター） 2019/03/08 31. Antibiotics may enhance the efficacy of gemcitabine treatment for advanced pancreatic cancer （ポスター） 2018/10/21 32. Dynamic change of immune-related gene expression status during chemoradiotherapy in locally advanced esophageal cancer （ポスター） 2018/10/20 33. Regorafenib療法のラーニングカーブ評価 （ポスター） 2018/07/20 34. フッ化ピリミジン不応・不耐の高度腹膜転移を伴う胃癌に対するタキサンを用いた二次治療の有効性・安全性の検討 （ポスター） 2018/07/20 35. Phase I study of the anti-heparin binding-EGF antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer （ポスター） 2018/04 36. Clinical Implication of Morphological Changes of Ramucirumab in Metastatic Gastric Cancer  2017/07/27 37. Early morphologic change (EMC) caused by regorafenib (REGO) in patients (pts) with metastatic colorectal cancer (mCRC) （一般） 2017/07 38. Development of new treatments and clinical practice for gastric cancer with peritoneal metastasis. （シンポジウム・ワークショップ・パネルディスカッション等） 2017/03 5件表示 全件表示(38件)